Corpus Intelligence IC Memo — RICHMOND UNIVERSITY MEDICAL CENTER 2026-04-26 13:28 UTC
IC Memo — RICHMOND UNIVERSITY MEDICAL CENTER
Investment Committee Memorandum | NY | 215 beds | Grade C | EBITDA uplift $28.5M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

RICHMOND UNIVERSITY MEDICAL CENTER

CCN 330028 | RICHMOND, NY | 215 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

RICHMOND UNIVERSITY MEDICAL CENTER is a 215-bed suburban community hospital in RICHMOND, NY with $387.4M in net patient revenue and a -18.9% operating margin. The hospital serves a payer mix of 22.1% Medicare, 10.4% Medicaid, and 67.5% commercial.

Thesis: Undervalued. Our ML models identify $28.5M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -18.9% to -11.5% (+736bps).

Net Revenue HCRIS$387.4M
Current EBITDA COMPUTED$-73.1M
Operating Margin COMPUTED-18.9%
Occupancy HCRIS80.3%
Revenue / Bed COMPUTED$1.8M
Net-to-Gross HCRIS25.3%
Distress Probability ML41.5%

2. Market Context & Competitive Position

196
NY Hospitals
-17.5%
State Median Margin
96
Comparable Hospitals

NY has 196 Medicare-certified hospitals with a median operating margin of -17.5%. The target's margin of -18.9% places it below the state median. Among 96 size-comparable peers (108-430 beds), the median margin is -17.8%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (108-430), prioritizing same-state peers. 96 hospitals in the comp set.

HospitalStateBedsRevenueMargin
RICHMOND UNIVERSITY MEDICAL CE (Target)NY215$387.4M-18.9%
LENOX HILL HOSPITALNY415$1.32B-35.1%
HOSPITAL FOR SPECIAL SURGERYNY200$1.12B-29.3%
NYC HEALTH+HOSPITAL/KINGS COUNNY381$1.03B-15.0%
ST. FRANCIS HOSPITALNY364$889.3M2.0%
WHITE PLAINS HOSPITALNY292$884.7M8.7%
ELMHURST HOSPITAL CENTERNY358$862.7M-9.5%
ROSWELL PARK CANCER INSTITUTENY142$772.3M-40.1%
VASSAR BROTHERS MEDICAL CENTERNY340$735.1M-2.6%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $28.5M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$8.1M+210bp18mo
Cost to Collect4.5%2.5%$7.7M+200bp12mo
Denial Rate Reduction12.0%6.5%$7.7M+198bp12mo
A/R Days Reduction5200.0%3800.0%$4.7M+122bp9mo
Clean Claim Rate88.0%96.0%$248K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$8.1M
Cost to Collect
$7.7M
Denial Rate Reduction
$7.7M
A/R Days Reduction
$4.7M
Clean Claim Rate
$248K
Total EBITDA Uplift$28.5M
Current EBITDA$-73.1M
+ RCM Uplift+$28.5M
Pro Forma EBITDA$-44.6M
Current Margin-18.9%
Pro Forma Margin-11.5%
WC Released (1x)$14.9M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-112.5M$-197.3M0.00x-100.0%
Base (11x exit)10.0x11.0x$-112.5M$-253.6M0.00x-100.0%
Bull Case9.0x11.0x$-101.3M$-196.0M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-101.3M$-243.8M0.00x-100.0%
Bear Case11.0x10.0x$-123.8M$-303.3M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-123.8M$-373.9M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 96 hospitals with 108-430 beds
  • Same-state prioritization (n=97)
  • Comp margins: P25=-28.6% / P50=-17.8% / P75=-9.4%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.